Premature Ejaculation Spray Enables Men To Last Six
Times Longer After Penetration
Men with premature ejaculation who used a topical spray five minutes before
intercourse were able to delay their orgasm six times longer than normal,
according to a study in the April issue of BJU International.
hundred men with clinically diagnosed lifelong premature ejaculation (PE) from
31 centres in the UK, Czech Republic, Hungary and Poland, were randomised into
two groups. Two hundred used the PSD502 spray, which contains 7.5mg of lidocaine
and 2.5mg of prilocaine, and 100 used a placebo spray with no active
Every time they had intercourse during the three-month study
period, each couple measured the time from vaginal penetration to ejaculation
with a stopwatch. The men were asked to abstain from sexual activity or
masturbation for 24 hours before each recorded encounter.
The time from
penetration to ejaculation increased from an average of 0.6 minutes to 3.8
minutes in the medicated group and to just 1.1 minutes in the placebo
When these figures were adjusted to take account of any variations
between the two groups, these showed that the treatment group were able to last
6.3 times longer after penetration when they used the spray. The placebo group
lasted 1.7 times longer.
"Premature ejaculation can be a very distressing
condition for men and can cause distress, frustration and make them avoid sexual
intimacy" says lead researcher Professor W Wallace Dinsmore from the Royal
Victoria Hospital, Belfast, UK.
The research team used the evidence-based
definition of lifelong PE developed by the International Society for Sexual
Medicine to select their study subjects. This states that ejaculation occurs
within about one minute of vaginal penetration in the majority of
"Because this definition was only launched in 2008, studies
have yet to determine the prevalence of lifelong PE in the male population" says
Professor Dinsmore. "But previous research suggests that as many as 40% of men
will experience premature ejaculation at some time in their lives."
300 men who took part in the phase three, multicentre, double-blind, randomised
study had an average age of 35. The majority had used other treatments before,
the most common being oral antidepressants.
After three months of
treatment the researchers reported that:
-- 90% of the men in the
treatment group were able to delay ejaculation for more than one minute
following vaginal penetration, compared with 54% in the placebo group.
74% of men in the treatment group managed to last more than two minutes before
ejaculation, compared with 22% in the placebo group.
-- 62% of men in the
treatment group said their orgasms were 'good' or 'very good' after three
months, compared with 20% before the study started. The figures for the placebo
group were slightly lower at the end (19%) than at the start (21%).
66% of men in the treatment group said the medication was 'good' or 'excellent'
compared with 15% in the placebo group.
-- A significantly higher
percentage of the patients and partners in the treatment group reported
improvements when it came to perceived control, personal distress, satisfaction
with sexual intercourse and interpersonal difficulties.
-- There were no serious adverse events reported during the study. Adverse
treatment-related reactions were reported by five men and six women from the
treatment group and one man from the placebo group. The most common problems
were loss of erection and a burning sensation in the vagina.
shows that when the PSD502 spray was applied to the man's penis five minutes
before intercourse it improved both sexual performance and sexual satisfaction,
which are key factors in treating premature ejaculation" says Professor
"It was well tolerated by both patients and their partners,
with no systemic side effects and a low incidence of localised effects and was
rated favourably by the majority of users.
"We believe that this shows
that PSD502 offers significant advantages over other therapies being developed
for the treatment of premature ejaculation."
Source: Wiley - Blackwell
Dr. Anand Jhawar